Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

RVMD

Revolution Medicines, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1628171Held by 9 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$0.00B
Net Income FY2025
$(1.13B)
EPS (Basic, as reported)
$-5.95
Net Margin FY2025
—
ROE FY2025
-69.3%
Total Equity
$1.63B
Shares Out
214M
Business description

Revolution Medicines, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2018–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 20 → 0
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023⚑FY2024FY2025
Revenue20504329351200
Research & development(51)(92)(132)(187)(253)(423)(592)(987)
General & administrative(9)(12)(21)(30)(41)(76)(97)(195)
Total operating expenses(60)(104)(154)(217)(294)(499)(690)(1,182)
Operating income(40)(54)(111)(188)(258)(487)(690)(1,182)
Interest expense0000000(24)
Interest & investment income12219478791
Other income (expense), net(1)2219478951
Pre-tax income(42)(52)(109)(187)(249)(440)(601)(1,131)
Income tax expense—(4)000(4)(1)0
Net income(42)(48)(108)(187)(249)(436)(600)(1,131)
EPS — basic——($2.01)($2.57)($3.08)($3.86)($3.58)($5.95)
EPS — diluted——($2.01)($2.57)($3.08)($3.86)($3.58)($5.95)
Shares outstanding — basic (M)——557381113168190
Shares outstanding — diluted (M)——557381113168190
  • ⚑ Weighted-average shares changed ×1.49 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.